Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs
Autore:
Naber, D; Moritz, S; Lambert, M; Rajonk, F; Holzbach, R; Mass, R; Andresen, B; Frank, P; Rudiger, H; Reinhard, M; Burghard, A;
Indirizzi:
Univ Hamburg, Krankenhaus Eppendorf, Clin Psychiat & Psychotherapy, D-20246 Hamburg, Germany Univ Hamburg Hamburg Germany D-20246 hotherapy, D-20246 Hamburg, Germany
Titolo Testata:
SCHIZOPHRENIA RESEARCH
fascicolo: 1-2, volume: 50, anno: 2001,
pagine: 79 - 88
SICI:
0920-9964(20010530)50:1-2<79:IOSPSW>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEGATIVE SYMPTOMS; DEFICIT SYNDROME; HALOPERIDOL; EXPERIENCE; NEUROLEPTICS; RISPERIDONE; OLANZAPINE; MEDICATION; QUALITY; SCALE;
Keywords:
atypical antipsychotic; neuroleptics; schizophrenia; well-being;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Naber, D Univ Hamburg, Krankenhaus Eppendorf, Clin Psychiat & Psychotherapy, Martinistr 52, D-20246 Hamburg, Germany Univ Hamburg Martinistr 52 Hamburg Germany D-20246 burg, Germany
Citazione:
D. Naber et al., "Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs", SCHIZOPHR R, 50(1-2), 2001, pp. 79-88

Abstract

Recent research indicates that subjective well-being is a major determinant of medication compliance in schizophrenia. However, it is yet unresolved whether atypical neuroleptics differ regarding subjective side-effects. A self-report instrument has been constructed to evaluate 'subjective well-being under neuroleptics' (SWN). The primary aims of the present study were todevelop a short form of the SWN and to investigate the extent to which theatypical antipsychotic improves the patient's subjective well-being. The short form of the SWN was constructed following an item analysis basedon data from 212 schizophrenic patients medicated with either typical or atypical antipsychotics. The short form of the SWN showed sufficient internal consistency and good construct validity. The SWN was only moderately correlated with positive and negative syndrome scale (PANSS) scores or changes in psychopathology (r = -0.20 to -0.37). SWN-ratings in patients receiving olanzapine were superior compared to those of patients medicated with either clozapine or risperidone on three of five domains of well-being. Clozapine reduced global psychiatric symptoms significantly more than risperidone. It is concluded that the assessment of subjective well-being under antipsychotic treatment provides an independent outcome measure which is relevant to compliance. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/01/20 alle ore 20:26:29